Stocks are entering a tough period. Top small-cap strategist says buy these steady quality names

Jefferies flags that higher “rates for longer” and a sharp rise in government bond yields could pressure equities, but it identifies small/mid-cap buy-rated names it expects to be relatively resilient. Top ideas include McCormick (Jefferies $62 price target, ~14% above the prior close) despite its ~20% YTD drawdown and risk from the proposed multi-bilion Unilever food-vertical merger, Okta (net revenue retention re-accelerated to 107% with a “year of harvesting” setup) and Citizens Financial (Jefferies $90 price target, ~28% upside). The note is a risk-management play rather than a clear bullish catalyst, with yield-driven macro uncertainty remaining the key overhang.

Analysis

Higher yields are not a blanket negative; they create a sharp bifurcation between cash-generative financials and duration-heavy growth. CFG is the cleaner beneficiary if funding stays sticky: every incremental move up in asset yields should drop through faster than deposit costs for a few quarters, but the trade breaks if credit softens or deposit betas reprice suddenly. The market is likely still underweight the possibility that a “higher for longer” tape improves bank earnings before it hurts loan demand.

OKTA is the most fragile on a rates basis even with improving operating momentum. The business can keep compounding if security spend stays priority-one, but the stock already reflects a lot of that optimism; rising real yields raise the discount rate on a name whose multiple depends on sustained reacceleration. That makes OKTA more of a selective long-on-pullback than a momentum chase, especially if the next data points show any pipeline conversion slippage.

MKC is the defensive quality name in the group: its mix gives it more insulation from U.S. discretionary weakness and more pricing discipline than broader consumer staples. The underappreciated issue is that any large 2026 transaction/integration path can suppress the multiple near term even if the strategic logic is sound, so the stock may work better as a 6-18 month compounder than as a quick rates hedge. The consensus is probably too focused on factor exposure and not enough on balance-sheet quality and earnings visibility; however, if yields are rising because growth is rolling over, even low-beta small caps can de-rate.

Key Decisions for Investors

• Long CFG vs short IWM for 1-3 months: express the view that rate pressure hurts the index multiple more than CFG’s near-term NIM expansion. Falsify if the 10Y yield rolls over materially or CFG guidance points to deposit-cost acceleration.
• Use OKTA as a pullback buy, not a chase: initiate only on a 10-15% retracement or after the next rates spike. Risk/reward is attractive only if the market keeps buying cyber spend while the multiple compresses to a more reasonable level.
• Add MKC on weakness for a 6-12 month defensive compounder view, but keep sizing modest until integration/transaction timing is clearer. A cleaner relative-value version is long MKC / short TGT if consumer weakness deepens.
• Watch CFG quarterly prints for deposit beta, NIM, and charge-offs before adding aggressively. If NIM expansion stalls while credit costs rise, the core thesis is invalidated quickly.
• For OKTA, consider short-dated downside protection around CPI/Fed windows if yields keep grinding higher. The stock is more vulnerable to real-rate moves than the fundamental improvement alone would suggest.